LAVA Therapeutics N.V. (LVTX)
- Previous Close
2.8300 - Open
2.8000 - Bid 2.7000 x 100
- Ask 2.7600 x 100
- Day's Range
2.6391 - 2.8200 - 52 Week Range
1.1310 - 6.4700 - Volume
112,130 - Avg. Volume
1,850,590 - Market Cap (intraday)
71.769M - Beta (5Y Monthly) 0.63
- PE Ratio (TTM)
-- - EPS (TTM)
-1.5700 - Earnings Date Jun 6, 2024 - Jun 10, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.
www.lavatherapeutics.comRecent News: LVTX
Performance Overview: LVTX
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LVTX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LVTX
Valuation Measures
Market Cap
75.52M
Enterprise Value
-13.73M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
11.35
Price/Book (mrq)
1.48
Enterprise Value/Revenue
-2.03
Enterprise Value/EBITDA
0.34
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-22.06%
Return on Equity (ttm)
-61.18%
Revenue (ttm)
6.77M
Net Income Avi to Common (ttm)
-41.97M
Diluted EPS (ttm)
-1.5700
Balance Sheet and Cash Flow
Total Cash (mrq)
95.57M
Total Debt/Equity (mrq)
12.34%
Levered Free Cash Flow (ttm)
-24.82M
Research Analysis: LVTX
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell